Skip to content

Examining What Works for Whom and How in Mindfulness-Based Cognitive Therapy (MBCT) for Recurrent Depression: A Moderated-Mediation Analysis in the PREVENT Trial (in press)

Jesus Montero-Marin, Verena Hinze, Shannon Maloney, Anne Maj van der Velden, Rachel Hayes, Edward R. Watkins, Sarah Byford, Tim Dalgleish, Willem Kuyken

preprint DOI: 10.31219/osf.io/rsvnm (opens in new tab)

Study at a glance

AI-extracted from the abstract
Characteristics Secondary analysis of a randomized controlled trial
Sample size 424
Population Adults with at least 3 previous major depressive episodes, in full or partial remission (below threshold for a current episode), taking antidepressant medication, recruited from primary care practices in the UK
Duration 24-month follow-up with assessments at pre, post, 9, 12, 18, and 24 months
Measures Beck Depression Inventory-II (BDI-II), Five Facets of Mindfulness Questionnaire (FFMQ)
Topics Depression Meditation
Key findings Mindfulness skills mediated the relationship between trial arm allocation (MBCT-TS vs. maintenance-ADM) and the linear rate of depressive symptom change over 24 months, and this mediation was moderated by baseline depression severity. Conditional indirect effects were larger for higher severity (-0.42, expected mean BDI-II reduction 10 points) than for lower severity (-0.15, expected mean BDI-II reduction 3.5 points). The authors conclude that patients with higher depression severity may benefit most from MBCT-TS for residual symptoms.

Abstract

Background: Personalized management of recurrent depression, considering individual patient characteristics, is crucial.

Aims: This study evaluates the potentially different mediating role of mindfulness skills in managing recurrent depression using mindfulness-based cognitive therapy (MBCT) among patients with varying depression severity.

Method: Data from the PREVENT trial, comparing MBCT (with antidepressant medication (ADM) tapering support, MBCT-TS) vs. maintenance-ADM, was used. The study included pre, post, 9-, 12-, 18-, and 24-month follow-ups. Adult patients with ≥3 previous major depressive episodes, in full/partial remission (below threshold for a current episode), on ADM, were assessed for eligibility in primary care practices in the UK. Patients were randomized (1:1) to MBCT-TS or maintenance-ADM. We used the Beck Depression Inventory-II to evaluate depressive symptom changes over the six time points. Pre-post treatment, we employed the Five Facets of Mindfulness Questionnaire to gauge mindfulness skills. Baseline symptom and history variables were used to identify patients with varying severity profiles. We conducted Latent Profile Moderated-Mediation Growth Mixture Models.

Results: A total of 424 patients (mean (SD) age=49.44 (12.31) years; with 325 (76.7%) self-identified as female) were included. A mediating effect of mindfulness skills, between trial arm allocation and the linear rate of depressive symptoms change over 24 months, moderated by depression severity, was observed (moderated-mediation index=-0.27, 95%CI=-0.66, -0.03). Conditional indirect effects were -0.42 (95%CI=-0.78, -0.18) for higher severity (expected mean BDI-II reduction=10 points), and -0.15 (95%CI=-0.35, -0.02) for lower severity (expected mean BDI-II reduction=3.5 points).

Conclusions: Mindfulness skills constitute a unique mechanism driving change in MBCT (vs. maintenance-ADM). Patients with higher depression severity may benefit most from MBCT-TS for residual symptoms. It is unclear if these effects apply to those with a current depressive episode. Future research should investigate individuals who are not on medication. This study provides preliminary evidence for personalized management of recurrent depression.

Comparable studies

Other randomized controlled trials on depression, most cited first.

Study Year Design Participants
A Randomized Trial of an N-methyl-D-aspartate Antagonist in Treatment-Resistant Major Depression Subjects with DSM-IV major depression (treatment resistant) 2006 Randomized, placebo-controlled, double-blind crossover study n = 18
Prevention of relapse/recurrence in major depression by mindfulness-based cognitive therapy. Recovered recurrently depressed patients 2000 Randomized controlled trial n = 145
Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial Cancer patients with life-threatening diagnoses and symptoms of depression and/or anxiety 2016 Randomized controlled trial n = 51
Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial Patients with cancer-related anxiety and depression 2016 Double-blind, placebo-controlled, crossover trial n = 29
Mindfulness-Based Cognitive Therapy for Depression: Replication and Exploration of Differential Relapse Prevention Effects. Recovered recurrently depressed patients 2004 Randomized controlled trial n = 73

Explore topics